BLRX News and Press, BioLineRx Ltd. From 12/13/20

Looking For Biotech Penny Stocks Right Now? One of the most active sets of penny stocks in 2020 has been biotech stocks. Aside from the obvious push from COVID-19 vaccine candidates, companies are utilizing the increased attention to build upon novel treatment pipelines. Evidenced b...

BioLineRx Ltd. (BLRX) Q3 2020 Earnings Conference Call November 23, 2020 10:00 AM ET Company Participants Timothy McCarthy – LifeSci Advisors, LLC Phil Serlin – Chief Executive Officer Mali Zeevi – Chief Financial Officer Abi Vainstein – Vice President-Clinical Dev...

Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...

Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio...

BioLineRx (BLRX) Q3 results:Revenues: $0; R&D Expense: $3.5M (-37.5%); Net loss: ($4.6M) (-17.9%); loss/share: ($0.02) (+33.3%); Quick Assets: $20.8M ; CF Ops: ($17.8M) (+3.5%).During the quarter, the company reported interim analysis for Phase 2b BLAST study in consolidation AML that did...

Ashford Hospitality Trust (AHT) -21% on update of exchange offers for all outstanding series of preferred stock.BioLineRx (BLRX) -13% on Q3 earnings release.AIM ImmunoTech (AIM) -8% after AIM and Shionogi terminated their material transfer agreement.Niu Technologies (...

biolinerx (BLRX): Q3 GAAP EPS of -$0.02 beats by $0.32.Cash, cash equivalents and short-term bank deposits of $20.8MPress Release For further details see: biolinerx EPS beats by $0.32

BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Phase 3 GENESIS study in SCM showed statistically significant positive results for primary endpoint in interim analysis; enrollment halted early; topline data in H1 2021 - - Interim analys...

BioLineRx (BLRX) has announced that its lead drug candidate Motixafortide, will be evaluated in an investigator-initiated Phase 1b trial in patients suffering from acute respiratory distress syndrome ((ARDS)) secondary to COVID-19 and other respiratory viral infections.The primary endpoint of...

BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 PR Newswire TEL AVIV, Israel, Nov. 18, 2020 Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NAS...